MX2023008251A - Mutantes de fimh, composiciones con estos y uso de estos. - Google Patents
Mutantes de fimh, composiciones con estos y uso de estos.Info
- Publication number
- MX2023008251A MX2023008251A MX2023008251A MX2023008251A MX2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A
- Authority
- MX
- Mexico
- Prior art keywords
- fimh
- mutants
- polypeptides
- compositions therewith
- lectin domain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004856 Lectins Human genes 0.000 abstract 2
- 108090001090 Lectins Proteins 0.000 abstract 2
- 239000002523 lectin Substances 0.000 abstract 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21151126 | 2021-01-12 | ||
| PCT/IB2022/050166 WO2022153166A1 (en) | 2021-01-12 | 2022-01-11 | Fimh mutants, compositions therewith and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008251A true MX2023008251A (es) | 2023-07-26 |
Family
ID=74175646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008251A MX2023008251A (es) | 2021-01-12 | 2022-01-11 | Mutantes de fimh, composiciones con estos y uso de estos. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11725028B2 (enExample) |
| EP (1) | EP4277921A1 (enExample) |
| JP (2) | JP7532672B2 (enExample) |
| KR (2) | KR102746713B1 (enExample) |
| CN (1) | CN116888140A (enExample) |
| AR (1) | AR124604A1 (enExample) |
| AU (1) | AU2022207740B2 (enExample) |
| CA (1) | CA3207841A1 (enExample) |
| IL (1) | IL303954B2 (enExample) |
| MX (1) | MX2023008251A (enExample) |
| TW (1) | TW202241929A (enExample) |
| WO (1) | WO2022153166A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021144369A1 (en) | 2020-01-16 | 2021-07-22 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| TW202241929A (zh) | 2021-01-12 | 2022-11-01 | 美商詹森藥物公司 | ＦｉｍＨ突變體、其組成物及其用途 |
| EP4448002A1 (en) * | 2021-12-17 | 2024-10-23 | Pfizer Inc. | Polynucleotide compositions and uses thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JPH0655749B2 (ja) | 1989-09-20 | 1994-07-27 | 日本たばこ産業株式会社 | リピッドａ単糖類縁体 |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| US5593969A (en) | 1991-09-03 | 1997-01-14 | Igen Incorporated | Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| CA2284586C (en) | 1997-04-01 | 2011-02-08 | Ribi Immunochem Research, Inc. | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| US6500434B1 (en) | 1998-04-23 | 2002-12-31 | Medimmune, Inc. | Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| CZ301212B6 (cs) | 1998-10-16 | 2009-12-09 | Smithkline Beecham Biologicals S. A. | Vakcinacní prostredek |
| AU6349700A (en) * | 1999-07-15 | 2001-02-05 | Med Immune, Inc. | Fimh adhesin-based vaccines |
| WO2001025254A2 (en) | 1999-10-04 | 2001-04-12 | University Of Maryland Biotechnology Institute | Novel adjuvant comprising a lipopolysaccharide antagonist |
| WO2001078777A2 (en) | 2000-04-13 | 2001-10-25 | Mossman, Sally | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
| JP2004502447A (ja) | 2000-07-07 | 2004-01-29 | メディミューン，インコーポレイテッド | ＦｉｍＨアドへシンタンパク質および使用方法 |
| EP1313502A4 (en) | 2000-08-18 | 2005-10-19 | Medimmune Inc | ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS |
| WO2002102974A2 (en) * | 2000-12-08 | 2002-12-27 | Medimmune, Inc. | Mutant proteins, high potency inhibitory antibodies and fimch crystal structure |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| CN101019123A (zh) * | 2004-02-06 | 2007-08-15 | 科学与工业研究委员会 | 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法 |
| CN101355928B (zh) | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| JP5356807B2 (ja) | 2005-05-11 | 2013-12-04 | アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| HRP20181259T1 (hr) | 2008-02-20 | 2018-10-05 | Glaxosmithkline Biologicals S.A. | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica |
| LT2437753T (lt) | 2009-06-05 | 2016-12-12 | Infectious Disease Research Institute | Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos |
| US11510875B2 (en) | 2012-02-07 | 2022-11-29 | Access To Advanced Health Institute | Adjuvant formulations comprising TLR4 agonists and methods of using the same |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9415101B2 (en) | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9415097B2 (en) | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| EA035991B9 (ru) | 2014-02-24 | 2020-10-21 | Глаксосмитклайн Байолоджикалс С.А. | Новый полисахарид и его применения |
| EP3693379A1 (en) | 2015-05-13 | 2020-08-12 | University of Washington | Compositions and methods for treatment and prevention of uropathogenice. coli |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| JP2020534261A (ja) * | 2017-09-08 | 2020-11-26 | ザ ユニバーシティ オブ ブリストル | 膜へのタンパク質送達 |
| TW201946650A (zh) | 2018-03-12 | 2019-12-16 | 美商詹森藥物公司 | 針對腹內感染之疫苗 |
| EP4077372A1 (en) * | 2019-12-20 | 2022-10-26 | Vib Vzw | Nanobody exchange chromatography |
| WO2021144369A1 (en) * | 2020-01-16 | 2021-07-22 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| TW202241929A (zh) | 2021-01-12 | 2022-11-01 | 美商詹森藥物公司 | ＦｉｍＨ突變體、其組成物及其用途 |
-
2022
- 2022-01-11 TW TW111101159A patent/TW202241929A/zh unknown
- 2022-01-11 KR KR1020237026809A patent/KR102746713B1/ko active Active
- 2022-01-11 AU AU2022207740A patent/AU2022207740B2/en active Active
- 2022-01-11 EP EP22700099.9A patent/EP4277921A1/en active Pending
- 2022-01-11 US US17/573,249 patent/US11725028B2/en active Active
- 2022-01-11 MX MX2023008251A patent/MX2023008251A/es unknown
- 2022-01-11 AR ARP220100049A patent/AR124604A1/es unknown
- 2022-01-11 KR KR1020247041946A patent/KR20250007029A/ko active Pending
- 2022-01-11 CA CA3207841A patent/CA3207841A1/en active Pending
- 2022-01-11 WO PCT/IB2022/050166 patent/WO2022153166A1/en not_active Ceased
- 2022-01-11 IL IL303954A patent/IL303954B2/en unknown
- 2022-01-11 CN CN202280009667.0A patent/CN116888140A/zh active Pending
- 2022-01-11 JP JP2023541784A patent/JP7532672B2/ja active Active
-
2023
- 2023-06-26 US US18/341,018 patent/US12297238B2/en active Active
-
2024
- 2024-04-22 JP JP2024068916A patent/JP2024109576A/ja active Pending
-
2025
- 2025-04-08 US US19/173,414 patent/US20250289854A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220220159A1 (en) | 2022-07-14 |
| JP7532672B2 (ja) | 2024-08-13 |
| AU2022207740B2 (en) | 2024-06-06 |
| US11725028B2 (en) | 2023-08-15 |
| IL303954B1 (en) | 2024-12-01 |
| AU2022207740A1 (en) | 2023-06-29 |
| US20250289854A1 (en) | 2025-09-18 |
| KR20250007029A (ko) | 2025-01-13 |
| KR102746713B1 (ko) | 2024-12-24 |
| TW202241929A (zh) | 2022-11-01 |
| US12297238B2 (en) | 2025-05-13 |
| AR124604A1 (es) | 2023-04-12 |
| JP2024109576A (ja) | 2024-08-14 |
| JP2024502854A (ja) | 2024-01-23 |
| AU2022207740A9 (en) | 2024-09-05 |
| EP4277921A1 (en) | 2023-11-22 |
| IL303954B2 (en) | 2025-04-01 |
| KR20230125842A (ko) | 2023-08-29 |
| IL303954A (en) | 2023-08-01 |
| WO2022153166A1 (en) | 2022-07-21 |
| CN116888140A (zh) | 2023-10-13 |
| US20230406890A1 (en) | 2023-12-21 |
| CA3207841A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121066A1 (es) | Mutante de fimh, composiciones que lo contienen y uso del mismo | |
| MX2023008251A (es) | Mutantes de fimh, composiciones con estos y uso de estos. | |
| CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| MY166228A (en) | Compositions comprising mixtures of semifluorinated alkanes | |
| NZ770137A (en) | Lactobacillus gasseri kbl697 strain and use thereof | |
| MX2018013622A (es) | Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada. | |
| MX2022008663A (es) | Composiciones alergenicas mixtas y metodos de uso de las mismas. | |
| BR112018017031A2 (pt) | formulações de antagonista de il-6 e usos das mesmas | |
| AR104835A1 (es) | Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas | |
| MX2017014082A (es) | Nuevas proteinas especificas para cd137. | |
| BR112018008684A2 (pt) | formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| BR112021006598A2 (pt) | composição farmacêutica líquida, e, kit | |
| BR112018016912A2 (pt) | novo antígeno para uso na vacina contra malária | |
| BR112019008349A2 (pt) | composição de peptídeos, e, utilização de uma composição. | |
| CO2023013465A2 (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| PE20151978A1 (es) | Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo | |
| BR112018067946A2 (pt) | formulações tópicas contendo ciclosporina e usos das mesmas | |
| MX2020009733A (es) | Composiciones. | |
| BR112019017393A2 (pt) | formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas | |
| PE20151866A1 (es) | Composiciones nutricionales que contienen un componente peptidico con propiedades estimulantes de adiponectina y usos del mismo | |
| MA45172B1 (fr) | Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées | |
| Behera et al. | Biochemical analysis and antitumour effect of Abrus precatorius agglutinin derived peptides in Ehrlich's ascites and B16 melanoma mice tumour model | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. |